Production and characterisation of a C595 antibody-99mTc conjugate for immunoscintigraphy of bladder cancer

Urological Research
M S SimmsM C Bishop

Abstract

Current radiological techniques for staging bladder cancer are inaccurate, especially in the identification of pelvic lymph node metastases. Immunoscintigraphy has the potential to offer improved staging for bladder cancer. The aim of this study was to label the anti-MUC1 monoclonal antibody C595 with 99mtechnetium (Tc), the most widely used diagnostic radionuclide, and assess the potential of the resultant conjugate for intravenous immunoscintigraphy of bladder cancer. A direct, reduction-mediated technique was used to label the antibody. The resultant conjugate was shown to be highly immunoreactive, stable and bound specifically to MUC1. The ability of the conjugate to bind to bladder tumours was demonstrated in an ex vivo model where the mean tumour:normal urothelial uptake was 5.7:1 and by intravesical administration in patients with bladder cancer where the mean tumour:normal urothelial uptake was 20.4:1. The ability of the conjugate to localise MUC1-expressing tumours was demonstrated in a nude mouse xenograft model. A conjugate of 99mTc-C595 has been produced and characterised, and it may be suitable for intravenous immunoscintigraphy, a potential novel staging tool for bladder cancer.

Citations

Jan 10, 2004·The Journal of Urology·Kent G KrejciEugene D Kwon
Jul 14, 2018·Indian Journal of Pathology & Microbiology·Ipek Isik GonulSinan Sozen
Oct 21, 2014·Contrast Media & Molecular Imaging·Saeed ShanehsazzadehMohammad Ali Oghabian
Apr 7, 2021·Molecular Pharmaceutics·Fariba MalekiKambiz Varmira

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.